NEW YORK (360Dx) – Roka Bioscience said after the close of the market on Thursday that its first quarter revenues grew 25 percent year over year.

For the three months ended March 31, the company posted $2.0 million in revenues, up from $1.6 million. Growth was driven by a 26 percent increase in the number of pathogen detection tests sold, Roka Bio said, as the number of Atlas molecular diagnostics instruments placed with customers grew to 54 in Q1 2017 compared to 44 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.